TerminatedInterventionalPhase 1Updated Feb 20, 2025
A Phase I Clinical Study Study of the Safety, Tolerability, and Pharmacokinetics of HX-1171 in Healthy Male Subjects | NCT01548391 | Trialant
Unknown statusInterventionalPhase 1Updated Mar 8, 2012
A Phase I Clinical Study Study of the Safety, Tolerability, and Pharmacokinetics of HX-1171 in Healthy Male Subjects
ClinicalTrials.gov ID
NCT01548391
Lead Sponsor
Biotoxtech Co., LtdINDUSTRY
Overall Status
Unknown status
Study Type
Interventional
Phase
Phase 1
Enrollment
66Estimated
Last Update Posted
Mar 8, 2012Estimated
Start Date
Mar 2012
Brief Summary
This study is designed to evaluate the safety, tolerability, and pharmacokinetics of HX-1171 in healthy male subjects.
Healthy
HX-1171
Ages Eligible for Study
Adult (18-64)
Sexes Eligible for Study
Male
Accepts Healthy Volunteers
Yes
Eligibility Criteria
Inclusion Criteria:
Adult males aged 20 to 40 years at screening.
Be able to comply with the requirement of the study. Subject must provide written informed consent prior to study participation.
Exclusion Criteria:
History or presence of liver, kidney, or nervous system disease, respiratory disorders, endocrinological disorders, hemato-oncologic, cardiovascular or psychiatric or gastrointestinal disorders.
History of known hypersensitivity to drugs including HX-1171.